Core Insights - AbbVie, Inc. (ABBV) and Bristol Myers Squibb (BMY) are prominent players in the biopharmaceutical industry, each with diverse portfolios and global reach [1][2] - Both companies have established strong positions in their respective therapeutic areas, making it challenging to choose between them based on fundamentals, growth prospects, and valuations [3] AbbVie Overview - AbbVie's flagship drug, Humira, has lost patent protection, leading to significant sales erosion due to biosimilar competition, particularly in 2024 and expected to worsen in 2025 [4] - The acquisition of Allergan for $63 billion has diversified AbbVie's product offerings and reduced reliance on Humira [4] - AbbVie's immunology drugs, Skyrizi and Rinvoq, are performing well, particularly in treating inflammatory bowel diseases, helping to offset Humira's declining sales [5] - AbbVie has a robust oncology portfolio with drugs like Imbruvica and Venclexta, with recent label expansions increasing the patient population for Venclexta [6] - The approval of Vyalev for advanced Parkinson's disease in October 2024 further enhances AbbVie's portfolio [6] - AbbVie is pursuing promising R&D initiatives, including next-generation immunology approaches and innovative therapies for neuropsychiatric disorders, alongside active M&A strategies [7] - As of March 31, 2025, AbbVie reported $64.5 billion in long-term debt and $5.4 billion in short-term obligations, with cash and equivalents around $5.2 billion [8] Bristol Myers Squibb Overview - BMY's Growth Portfolio, including drugs like Reblozyl and Opdualag, has stabilized revenue amid generic competition for legacy drugs [9][10] - Reblozyl has shown strong performance since its approval, contributing significantly to revenue growth [10] - Opdivo continues to gain momentum with consistent label expansions, and recent FDA approvals for new drugs like Cobenfy broaden BMY's portfolio [11][12] - Despite new drug launches, BMY faces revenue pressure from legacy drugs, which saw a 20% decline in the first quarter due to generic competition [13] - BMY's long-term debt stood at $46.1 billion as of March 31, 2025, with cash and equivalents of $12.1 billion [14] Financial Estimates and Performance - The Zacks Consensus Estimate for AbbVie's 2025 sales indicates a 6.6% year-over-year increase, with EPS expected to improve by 20.65, although recent estimates have declined [15] - For BMY, the 2025 sales estimate suggests a 4.13% decrease, while EPS is projected to increase by 487.83%, influenced by low EPS figures in 2024 [17] - Year-to-date, ABBV shares have gained 11.8%, while BMY shares have decreased by 11.2%, compared to a 1.6% gain in the large-cap pharma industry [18] - In terms of valuation, ABBV trades at 14.76X forward earnings, slightly higher than BMY's 7.60X, while the industry average is 15.16X [19] - BMY offers a higher dividend yield of 5.20% compared to ABBV's 3.4%, which is attractive for investors [22] Investment Outlook - Both companies are considered safe investments in the biopharma sector, but selecting one over the other is complex due to their current Zacks Rank of 3 (Hold) [23] - AbbVie's diverse portfolio and strong performance from its immunology drugs position it favorably despite challenges from declining Humira sales [24] - BMY's efforts to counteract revenue declines from legacy drugs through new approvals and acquisitions are commendable, but challenges remain for 2025 [25]

金十图示：2025年07月11日（周五）亚盘市场行情 @ JIN10.COM 金十数据 | 一个交易工具 | 现货铂金 XPTUSD | 1361.580 | +1.030 | +0.08% | | --- | --- | --- | --- | | 现货铝金 XPDUSD | 1187.890 | -6.689 | -0.56% | | 黄金(COMEX) GC | 3340.100 | +7.100 | +0.21% | | 白银(COMEX) SI | 37.715 | +0.090 | +0.24% | FOREIGN EXCHANGE 欧元/美元 -0.16% 1.168 EURUSD 英镑/美元 -0.13% 1.356 GBPUSD 美元/日元 IN 146.734 +0.34% USDJPY 澳元/美元 -0.05% 0.659 AUDUSD 美元/瑞郎 +0.07% 0.797 USDCHF | | 纽元/美元 NZDUSD | 0.603 | -0.04% | | --- | --- | --- | --- | | 机 | 英镑/日元 GBPJPY | 198.993 | +0.21% | ...

威迈斯 20250707 摘要 威迈斯 2024 年车载电源业务营收占比 85%，虽较 2023 年下降，但仍 是核心业务。公司同时布局 EVCC、无线充系统及液冷充模块技术，拓 展产品线。2024 年公司整体销量达 240 万套，但受下游车企价格战影 响，行业单价有所下降。 国内市场，威迈斯车载电源产品在上汽集团、领跑汽车占据主导份额， 并是理想汽车的独家供应商，在长安、奇瑞及吉利中份额约为 60%。剔 除车企自供部分，威迈斯在国内第三方供应商市场中市占率约为 30%， 位居第一。 威迈斯深度绑定 Stellantis，并获得雷诺、阿斯顿马丁及法拉利等公司 的定点。Stellantis 新平台车型预计 2025 年放量，有望带动威迈斯海 外收入增长。2024 年公司来自 Stellantis 的销售额折合人民币 6 亿元， 占公司整体营收 9%。 威迈斯采用磁集成技术，共用 PCBA 功率板实现 OBC 和 DCDC 功能， 降低成本并提升功率密度。公司在 800 伏车载电源集成产品领域进展领 先，已获得小鹏、理想、蓝图及智己等客户定点，并实现量产发货。 Q&A 威迈斯在国内和海外市场的表现如何？ 威迈斯成 ...

Key Takeaways BMY faces generic pressure on key drugs like Revlimid and Pomalyst, plus Medicare Part D headwinds. New drugs like Reblozyl, Opdualag and Breyanzi are driving growth amid strong uptake and new approvals. BMY trades at 7.34x forward earnings, below its average and the broader large-cap pharma industry.Bristol Myers (BMY) depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition.Legacy Portfolio is adversely impacted ...

金十图示：2025年06月23日（周一）亚盘市场行情 美国2年期国债收益率 | 现货铂金 XPTUSD | 1252.082 | -17.548 | -1.38% | | --- | --- | --- | --- | | 现货铝金 XPDUSD | 1036.834 | -7.275 | -0.70% | | 黄金(COMEX) GC | 3375.600 | -8.800 | -0.26% | | 白银(COMEX) SI | 36.005 | +0.055 | +0.15% | FOREIGN EXCHANGE | | 欧元/美元 EURUSD | 1.150 | -0.20% | | --- | --- | --- | --- | | | 英镑/美元 | | | | | GBPUSD | 1.343 | -0.15% | | =7 | 美元/日元 | 146.536 | +0.30% | | | USDJPY | | | | | 澳元/美元 AUDUSD | 0.642 | -0.41% | | | 美元/瑞郎 | 0.818 | +0.02% | | | USDCHF | | | | | 纽元/美元 ...

施耐德电气与 Nvidia 在 GTC Paris 联合宣布，一项全球性合作协议旨在开发专为 AI 数据中心设计的冷 却、管理和控制系统，以支持欧盟的 AI 行动计划。施耐德电气详细说明了其对于支持高达 1 MW 负载 机架的贡献。 借助此次合作，施耐德还公布了 EcoStruxure 系列新增产品，这些产品越来越多地针对高功率密度的 AI 集群设计。 新增产品包括预制、可扩展的数据中心舱，专为快速部署高密度工作负载而设计。预制模块化 EcoStruxure Pod 数据中心可按照订单定制并预先组装交付，支持最高达 1 MW 及以上的高密度机架。 谷歌近期也表示，其正在规划 1 MW 机架级 IT 硬件，以支持 AI 工作负载。 此外，施耐德还宣布推出 NetShelter SX Advanced Enclosures，该产品拥有更高、更深、更坚固的机架， 可承载配线和基础设施更多、更重的系统，同时还推出了为现代 AI 服务器高功率需求而更新的 NetShelter Rack PDU Advanced 电源分配单元。 NetShelter Open Architecture 是一款"灵感来源于" Open C ...

Arrowhead Pharmaceuticals (ARWR) FY Conference Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (ARWR) - **Event**: FY Conference held on June 09, 2025 - **Key Speakers**: James Hamilton (CMO and Head of R&D), Vince Ambulone (VP of Finance and IR) Key Points Industry Context - Arrowhead is positioned in the biotechnology sector, focusing on RNA interference (RNAi) therapeutics, particularly for rare diseases and metabolic disorders [5][6][8]. Financial Health - The company has successfully augmented its balance sheet, securing funding through 2028, which allows for multiple potential independent commercial launches [7][8][66]. Product Pipeline - **Plazasiran**: - First independent commercial launch anticipated with a PDUFA date set for November 18, 2025 [5][6]. - Targeting triglyceride lowering for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG) [6][20]. - Positive data from the PALISADE Phase III study supports its efficacy [6]. - **Ongoing Studies**: - Full enrollment for Phase III studies expected by mid-2025, with completion and subsequent launch into SHTG anticipated in 2026 [7][20]. - Additional studies targeting rare muscular diseases and obesity assets are also in the pipeline, with readouts expected later in 2025 [8]. Competitive Landscape - Arrowhead acknowledges the competitive market for triglyceride-lowering therapies, particularly with Ionis Pharmaceuticals' product, Olezarsen [19][20]. - The company believes that having multiple players in the market will enhance disease state education and patient access [18][20]. Regulatory and Market Strategy - Arrowhead is confident in its communications with the FDA regarding the approval process for Plazasiran, despite the uncertainties in the biotech sector [11][12]. - The company is preparing for potential pricing strategies, considering market dynamics and the competitive landscape [22][23]. Clinical Trials and Safety - The SHASTA-5 study is designed to assess pancreatitis risk in high-risk patients, which is crucial for payer acceptance, especially in European markets [27][28][36]. - Arrowhead is focused on demonstrating a material benefit in reducing acute pancreatitis events to enhance reimbursement prospects [28][37]. Future Developments - Arrowhead is exploring combination therapies with existing GLP-1 agents to enhance weight loss outcomes and improve patient adherence [60][62]. - The company is also advancing its CNS platform, targeting ATAXN2 and tau expression, with clinical trials expected to commence within the next 6-12 months [65]. Business Development - Arrowhead plans to pursue additional partnerships and collaborations to leverage its discovery engine and expand its pipeline [66][68]. - The company is open to product and discovery partnerships, particularly in the cardiometabolic space, to support its commercialization efforts [68]. Conclusion Arrowhead Pharmaceuticals is strategically positioned for growth with a robust pipeline and a strong financial foundation. The upcoming launch of Plazasiran and ongoing studies in various therapeutic areas highlight the company's commitment to addressing unmet medical needs in the biotechnology sector. The competitive landscape and regulatory environment will be critical factors influencing Arrowhead's market success in the coming years.

Company Overview - Bristol-Myers Squibb is a leading global specialty biopharmaceutical company focused on developing treatments for severe diseases [12] - The company has a diverse portfolio that includes blockbuster immuno-oncology drug Opdivo and essential immunology and cardiovascular drugs like Orencia and Eliquis [12] Financial Performance - For fiscal 2025, 11 analysts have revised their earnings estimate upwards in the last 60 days, increasing the Zacks Consensus Estimate by $0.10 to $6.85 per share [13] - Bristol-Myers Squibb boasts an average earnings surprise of 20.2% [13] Investment Ratings - The company currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A [13] - Bristol-Myers Squibb has a Momentum Style Score of B, and its shares have increased by 4.2% over the past four weeks [13] - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Bristol-Myers Squibb is recommended for investors' short list [14]

| | 现货掘变 XPDUSD | 975.272 | +1.253 | +0.13% | | --- | --- | --- | --- | --- | | | 黄金(COMEX) GC | 3304.800 | +5.100 | +0.15% | | | 白银(COMEX) SI | 33.390 | +0.005 | +0.01% | | | | FOREIGN EXCHANGE | | | | | 欧元/美元 EURUSD | 1.133 | | +0.02% | | | 英镑/美元 GBPUSD | 1.351 | | +0.01% | | == | 美元/日元 USDJPY | 144.204 | | -0.10% | | | 澳元/美元 AUDUSD | 0.644 | | +0.05% | | | 美元/瑞郎 USDCHF | 0.827 | | +0.01% | | | 纽元/美元 NZDUSD | 0.594 | | -0.03% | 金十图示：2025年05月28日（周三）亚盘市场行情 JIN10.COM 金十数据 | 一个交易工具 英镑/日元 -0.09% 194.787 GBPJPY ...

Core Viewpoint - Amgen and Bristol Myers Squibb are leading biotechnology companies with diverse portfolios, making it challenging to choose between them based on their fundamentals, growth prospects, challenges, and valuations [1][2]. Amgen (AMGN) - Amgen has a vast global footprint and a diverse portfolio, with growth products like Prolia, Xgeva, Evenity, Vectibix, Nplate, Kyprolis, and Blincyto stabilizing revenue despite declining sales from legacy drugs [3][4]. - Increased pricing pressures and competition from biosimilars are expected to negatively impact sales of Prolia and Xgeva starting in 2025 [4]. - Key drug Repatha is driving growth, and the approval of Tezspire for severe asthma has strengthened Amgen's portfolio [4][5]. - Amgen has promising candidates in its pipeline, including a broad phase III program on MariTide targeting obesity and type-II diabetes, with data readouts expected in the second half of 2025 [5]. - The acquisition of Horizon Therapeutics has expanded Amgen's rare disease business significantly [6]. - The Zacks Consensus Estimate for Amgen's 2025 sales indicates a year-over-year increase of 5.31%, with EPS expected to improve by 4.79% [13]. - Amgen's shares have gained 6.2% this year, trading at 13X forward earnings, indicating a higher valuation compared to BMY [16][17]. Bristol Myers Squibb (BMY) - BMY's growth portfolio, including drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, has stabilized revenue amid generic competition for legacy drugs [7][8]. - Reblozyl has shown strong performance in the U.S. and international markets, expected to contribute significantly in the coming decade [7]. - Opdivo maintains momentum with consistent label expansions, and the recent FDA approval of Cobenfy for schizophrenia broadens BMY's portfolio [9][10]. - Despite newer drugs boosting sales, generic competition for legacy drugs has led to a 20% decline in legacy portfolio revenues in Q1 due to impacts from Revlimid and others [11]. - BMY's strategy of acquiring promising companies has resulted in substantial debt, with long-term debt at $46.1 billion as of March 31, 2025 [12]. - The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.10%, while EPS suggests a significant increase of 499.13% [14]. - BMY's shares have lost 15.5% this year, trading at a lower valuation of 7.10 for forward earnings [16][17]. Comparison and Conclusion - Both companies offer attractive dividend yields, with BMY at 5.30% and AMGN at 3.49% [20]. - AMGN is viewed as a better pick currently due to solid fundamentals and recent positive estimate revisions, despite its higher valuation [23].